Shandong Xinhua Pharmaceutical Co Ltd (000756) - Total Assets
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) holds total assets worth CN¥9.24 Billion CNY (≈ $1.35 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 000756 total equity for net asset value and shareholders' equity analysis.
Shandong Xinhua Pharmaceutical Co Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Shandong Xinhua Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Xinhua Pharmaceutical Co Ltd's total assets of CN¥9.24 Billion consist of 41.3% current assets and 58.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.8% |
| Accounts Receivable | CN¥868.20 Million | 9.6% |
| Inventory | CN¥1.27 Billion | 14.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥565.04 Million | 6.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shandong Xinhua Pharmaceutical Co Ltd (000756) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Xinhua Pharmaceutical Co Ltd's current assets represent 41.3% of total assets in 2024, an increase from 36.8% in 2015.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2024, up from 10.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, unchanged from 6.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 14.1% of total assets.
Shandong Xinhua Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shandong Xinhua Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Shandong Xinhua Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.39 | 1.22 |
| Quick Ratio | 0.88 | 0.94 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥839.89 Million | CN¥1.02 Billion | CN¥470.74 Million |
Shandong Xinhua Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Xinhua Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.09 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 8.9% |
| Total Assets | CN¥9.02 Billion |
| Market Capitalization | $1.02 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Xinhua Pharmaceutical Co Ltd's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Xinhua Pharmaceutical Co Ltd's assets grew by 8.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)
The table below shows the annual total assets of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.02 Billion ≈ $1.32 Billion |
+8.85% |
| 2023-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
+0.25% |
| 2022-12-31 | CN¥8.27 Billion ≈ $1.21 Billion |
+12.73% |
| 2021-12-31 | CN¥7.33 Billion ≈ $1.07 Billion |
+3.37% |
| 2020-12-31 | CN¥7.09 Billion ≈ $1.04 Billion |
+10.21% |
| 2019-12-31 | CN¥6.44 Billion ≈ $941.79 Million |
+8.79% |
| 2018-12-31 | CN¥5.92 Billion ≈ $865.72 Million |
+12.18% |
| 2017-12-31 | CN¥5.27 Billion ≈ $771.70 Million |
+11.66% |
| 2016-12-31 | CN¥4.72 Billion ≈ $691.09 Million |
+5.13% |
| 2015-12-31 | CN¥4.49 Billion ≈ $657.34 Million |
-- |
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more